
Antonio M Grimaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2454855/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563
2	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncolmmunology, 2014, 3, e28780.	2.1	318
3	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 675-683.	2.0	230
4	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clinical Cancer Research, 2013, 19, 997-1008.	3.2	161
5	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	1.3	149
6	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. Journal of Translational Medicine, 2012, 10, 107.	1.8	112
7	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncolmmunology, 2015, 4, e1008842.	2.1	72
8	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncolmmunology, 2017, 6, e1261242.	2.1	59
9	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs, 2017, 31, 51-61.	2.2	46
10	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncolmmunology, 2018, 7, e1405206.	2.1	43
11	The role of MEK inhibitors in the treatment of metastatic melanoma. Current Opinion in Oncology, 2014, 26, 196-203.	1.1	39
12	Novel Approaches in Melanoma Prevention and Therapy. Cancer Treatment and Research, 2014, 159, 443-455.	0.2	36
13	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival Journal of Clinical Oncology, 2012, 30, 8573-8573.	0.8	13
14	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 2017, 27, 243-250.	0.6	12
15	Lean oncology: a new model for oncologists. Journal of Translational Medicine, 2012, 10, 74.	1.8	11
16	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. Melanoma Management, 2015, 2, 209-215.	0.1	7
17	A monocentric phase I study of vemurafenib plus cobimetinib plus PEC-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine, 2021, 19, 17.	1.8	6
18	Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. Cancers, 2021, 13, 1857.	1.7	5

#	Article	IF	CITATIONS
19	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, 2015, 13, .	1.8	2
20	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. Journal of Translational Medicine, 2015, 13, O8.	1.8	2
21	Vemurafenib beyond progression in a patient with metastatic melanoma. Anti-Cancer Drugs, 2015, 26, 464-468.	0.7	2
22	Clinical results of EGFR-targeted therapies in advanced colorectal cancer. European Journal of Cancer, Supplement, 2008, 6, 64-69.	2.2	1
23	Marker Utility for Combination Therapy. Methods in Molecular Biology, 2014, 1102, 97-115.	0.4	0